DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Capastat Sulfate (Capreomycin) - Published Studies

 
 



Published Studies Related to Capastat Sulfate (Capreomycin)

Research related to Capastat Sulfate (Capreomycin)

Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. [2010.02]

Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. [2008.04]

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. [2007.08]

Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. [2007.03.21]

Unilamellar vesicles as potential capreomycin sulfate carriers: preparation and physicochemical characterization. [2004.12.31]

UV spectroscopy and reverse-phase HPLC as novel methods to determine Capreomycin of liposomal fomulations. [2004.10.29]

Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model. [1994.12]

Other possibly related research studies

Treatment outcome of multidrug-resistant tuberculosis among Vietnamese immigrants. [2005.02]

[A case of pulmonary multiresistant Mycobacterium bovis tuberculosis in Madagascar] [2003]

[Pulmonary disease caused by nontuberculous mycobacteria after allogeneic hematopoietic stem cell transplantation--a case report and literature review] [2004.08]

A decade surveillance study of Mycobacterium xenopi disease and antimicrobial susceptibility levels in a reference teaching hospital of northern Italy: HIV-associated versus non-HIV-associated infection. [2004.07]

Hypokalemia among patients receiving treatment for multidrug-resistant tuberculosis. [2004.03]

Multidrug-resistant tuberculosis in pregnancy: case report and review of the literature. [2003.03]

Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. [2003.01]

[Pulmonary infection caused by Mycobacterium szulgai: a case report] [2002.05]

Treatment and prevention of multidrug-resistant tuberculosis. [1999.10]

Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. [1999.10]

The safety of antituberculosis medications during breastfeeding. [1998.12]

[Surgical treatment of patients with multi-resistant pulmonary tuberculosis--case reports] [1997]

Prevention and treatment of drug-resistant tuberculosis. [1996.10.01]

Clinical manifestation and outcome of tuberculosis in children with acquired immunodeficiency syndrome. [1996.05]

Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family. [1996.02.14]

Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital. [1994.10.10]

Antimycobacterial drugs. [1994.06]

Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. [1994.02]

Therapy of multidrug-resistant tuberculosis: lessons from studies with mice. [1993.11]

Pharmacology of the antimycobacterial drugs. [1993.11]

Renal magnesium wasting associated with therapeutic agents. [1991]

Immunosuppression by gramicidin S of experimental autoimmune uveoretinitis, pinealitis and autoimmune encephalomyelitis. [1990.09]

[Interactions of antitubercular drugs] [1988]

The efficacy of certain anti-tuberculosis drugs is affected by binding to alpha-1-acid glycoprotein. [2006.06]

Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. [2006.03]

Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. [2006.03]

A community-based TB drug susceptibility study in Mimika District, Papua Province, Indonesia. [2006.02]

[Tuberculosis caused by XDR resistant Mycobacterium tuberculosis in Poland. Microbiological and molecular analysis] [2007]

Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. [2007.11.15]

[Extensively drug-resistant tuberculosis] [2008.02]

Extensively drug-resistant tuberculosis in california, 1993-2006. [2008.08.15]

Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. [2008.06]

High levels of resistance to second-line anti-tuberculosis drugs among prisoners with pulmonary tuberculosis in Georgia. [2008.05]

Extensively drug-resistant tuberculosis in the United States, 1993-2007. [2008.11.12]

Extensively drug-resistant tuberculosis: new strains, new challenges. [2008.10]

Management of extensively drug-resistant tuberculosis in Peru: cure is possible. [2008.08.13]

Extensively drug resistance (XDR) tb is not always fatal. [2009.01]

Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. [2009.04]

Extensively drug-resistant tuberculosis in the UK: 1995 to 2007. [2009.06]

Multidrug-resistant to extensively drug resistant tuberculosis: what is next? [2008.11]

Extensively drug-resistant Mycobacterium tuberculosis during a trend of decreasing drug resistance from 2000 through 2006 at a Medical Center in Taiwan. [2008.10.01]

Factors associated with multidrug-resistant tuberculosis: comparison of patients born inside and outside of the Czech Republic. [2010.05]

Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. [2010.09]

Activity of drug combinations against dormant Mycobacterium tuberculosis. [2010.06]

Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent "as new use". [2010.06.01]

Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance. [2010.03]

Prevalence of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. [2009.10]

Simple and scalable method for peptide inhalable powder production. [2010.01.31]

Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia. [2009.10]

Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. [2009.11]

Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. [2011.08]

Management of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis: current status and future prospects. [2011.01]

Multicentre laboratory validation of the colorimetric redox indicator (CRI) assay for the rapid detection of extensively drug-resistant (XDR) Mycobacterium tuberculosis. [2011.04]

[Extensively drug resistant and extremely drug resistant tuberculosis forms after multi-drug resistant tuberculosis: new faces of the old disease]. [2011.01]

[Anti-tuberculosis drug resistance and therapeutic dead end]. [2010.11]

Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second line drugs. [2010.10]

Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia. [2010.10]

Drug resistance pattern in multidrug resistance pulmonary tuberculosis patients. [2010.04]

Therapy Of XDR TB with thioridazine a drug beyond patent protection but eligible for patent "as new use". [2010.06]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017